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Abstract Off-label drug use in paediatrics is associated
with an increased risk of adverse drug reactions. Any risk–
benefit analysis has to be based on value judgments that
should include parents' views. However, nothing is known
so far about the parents' perspective on this critical issue.
Therefore, a quantitative survey with parents of healthy and
chronically ill children was carried out (n=94). Knowledge
about the practise of off-label use is generally poor in both
groups. Surprisingly, this is also true for the parents of
children with chronic disease. Nine percent of the parents
of chronically ill children and 20% of the parents of healthy
children would refuse treatment with an off-label drug.
Parents who have poor knowledge about the practise of off-
label use tend to refuse to volunteer their child for study
participation. Therefore, the information of parents on the
off-label use of drugs is important to meet ethical standards
and to increase the parents' acceptance of medical studies
with children.
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Introduction
The off-label use of drugs in paediatrics, i.e. the prescrip-
tion of drugs which are not licensed for a specific age or
mode of application, is often described as an ethical
problem [1–3, 6, 10]. Children with chronic renal insuffi-
ciency, for example, often suffer from arterial hypertension.
They need long-term antihypertensive therapy with drugs
which, however, are not approved for children so far. Drugs
of first choice are angiotensin-converting enzyme inhib-
itors: captopril, enalapril and ramipril. Since clinical trials
involving children do not exist, the applied dosage results
from experience with adults. Empirical studies show that
the off-label use of drugs in paediatrics is connected with a
significantly increased risk of an adverse drug reaction [11,
16, 19]. This is due to the fact that these drugs are only
tested in and licensed for adult patients and the transfer of
knowledge to the paediatric population is sometimes
doubtful. As Collier argues, “The validity of such an
approach is questionable because there are such great
differences between adults and children, and even between
children of different ages, with regard for instance to the
pharmacodynamic and pharmacokinetic responses to drugs,
[…], and the effects of drugs on normal growth and
development” [6: p. 6]. There is a high incidence of off-
label use both in out-patient and in-patient settings, which
ranges from 10.5% up to 90% [4, 8, 15]. Off-label use is so
commonplace that it is often probably not specifically
mentioned when a drug is administered to a patient.
At least two ethical problems arise from this: first, if the
off-label use of drugs can be understood as a form of
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the question arises whether parents should explicitly be
informed about the character of the treatment.
1 Here, a
difficulty arises due to the fact that even some paedia-
tricians are not aware of the practise of off-label prescrip-
tions. In a study of Chalumeau et al., French paediatricians
were asked to comment whether their prescriptions were
off-label or not. In 92% of the cases, the paediatricians did
not recognise a drug's off-label status [5]. Secondly, the
ethical principle of non-maleficence calls for a reduction of
risks in the course of a medical treatment wherever
possible. This is particularly important in the case of
vulnerable groups like children [13, 14]. To minimise the
number of off-label treatments, one could either leave
patients untreated or increase the number of clinical trials in
the paediatric population, either way entailing severe ethical
problems involving complex risk–benefit analyses. How-
ever, so far, no systematic knowledge is available on the
preferences of parents in these cases. Do they accept off-
label use as inevitable or as the lesser of two evils? Would
they volunteer their child for clinical trials to reduce the
incidence of off-label treatments? As paediatricians have a
reputation for being cautious in relation to burdening their
little patients with clinical research, parents' views would
help to evaluate the pros and cons of yet another trial in the
paediatric population.
To come to know parents' views on off-label use, we
conducted an empirical survey with parents of chronically
sick and healthy children. We assumed that members of
both groups differ with regard to knowledge and evaluation
of this phenomenon, dependent on the degree of previous
clinical experience. While parents of healthy children
represent the ‘normal’ population and their typical level of
knowledge and normative judgments, parents of chronically
ill children may have achieved a kind of ‘expert status’ and
thus extensive knowledge about medical treatment. We also
assumed that parents of ill children differ in weighing risks
and benefits in treatment as well as in clinical studies with
their children.
Methods
In a first step, we developed a questionnaire on ethical
aspects of off-label use in paediatrics in close collaboration
with experienced paediatricians and parents of chronically
ill children. The questionnaire comprised three different
sections: First, we asked questions concerning the demo-
graphic facts, the family's and children's actual health
condition as well as their experience in clinical studies. In
the second part, we explored parental knowledge and views
of off-label use in paediatrics. Finally, the parents had to
assess whether they would volunteer their children for
participation in three different study scenarios. We assumed
that the answers depended on parental educational status,
the health condition of the child and experience with
clinical trials. We were particularly eager to know whether
the actual knowledge of parents about off-label use has an
influence on the overall acceptance of off-label treatment or
study participation. Fishers' exact test was used to analyse
associations in non-parametric categorical data. Statistical
significance is defined by a p value<0.05. The study was
approved by the Research Ethics Committee of the
University of Göttingen.
Participants
Parents of children with renal disease (group A) were
contacted via the Departments for Paediatrics at Göttingen
and Hanover University Hospitals in Lower Saxony.
According to the studies of Conroy et al. [7] and Knöppel
et al. [12], one can expect that between 31% and 67% of the
prescriptions in such a medical setting will be off-label. We
distributed 80 questionnaires to parents visiting out-patient
care in the time from June to September 2006 and received
back 43 (54%). Inclusion criteria were the age of children
(6 to 14 years), the length of contact with the hospital (at
least a half year) and the chronic state of the treated
condition. Children had a great variety of renal conditions
including milder forms of renal disease, renal insufficiency
and renal transplant. During routine hospital visits, parents
were informed by a consultant about the study and asked to
participate. They received the questionnaire and were asked
to send it back. The parents of healthy children (group B)
were contacted at a soccer club meeting in the city of
Kassel. For the control group, we chose parents from
children playing soccer in a club because these children are
normally healthy and need only minor health care inter-
ventions. In Germany, children who play soccer have to
pass a health test before joining the club. Moreover, soccer
in Germany is an all-class sport. We thus expected parents
to represent a broad educational background. Again, 80
questionnaires were distributed to this group and 51 (64%)
were sent back. Children of these parents were members of
the club and in good health condition. Fifteen (30%) of the
parents from group B reported some common but minor
chronic disease conditions (mostly asthma and neuro-
dermitis) in their families (Table 1).
1 For example, a recent study of El-Wakeel et al. [9] shows that
patients are very interested in information regarding possible treatment
risks and complications before giving informed consent.
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In group A (chronically ill children), the mean age of the
sick children was 9.9 years. Asked how often they usually
see a doctor, eight parents (19%) reported ‘one or more
visits per week’ and 15 parents (35%) ‘once a month’.
Eleven parents (26%) reported only ‘irregular’ health
contacts. Health care was in most cases delivered by a
paediatrician (22/51%) or a university hospital (23/54%).
Nine children (21%) of group A had already been included
in one or more clinical studies. Parents' educational status
was comparable to the German population as eight parents
(19%) hold a university degree or finished school with the
final secondary school examination, 29 parents (67%) with
the intermediate secondary school examinations and six
parents (14%) with the lower secondary school examina-
tions. In group B (healthy children), the children's mean age
was 9.5 years, and the parents' educational level was higher
than in the group A with 26 parents (51%) holding a
university degree or finishing school with the final
secondary school examination, 25 parents (49%) with the
intermediate secondary school examinations and none with
the lower secondary school examinations. In both groups,
questionnaires were mainly completed by the children's
mothers (79/84%).
Parents’ knowledge of drug use (Table 2)
The parents in both groups A and B showed great interest
in information on the mode of application and on possible
side effects of prescribed drugs. None out of group A and
only five out of group B (5%, n=94) answered that they
usually do not ask their physician for additional information
on the usage, mode of action or possible side effects of
prescribed drugs (p=0.04). In groups A and B, no parent
answered that she/he does not read leaflet instructions of a
newly prescribed drug. Twenty-two (23%, n=94) answered
that they ‘sometimes’ read the leaflet instruction, the
remaining 72 (77%, n=94) answered that they ‘always’
read the instruction. Additionally, 39 parents of group A
(91%) and 43 parents (84%) of group B indicated that their
physician ‘sometimes’ or ‘always’ draws their attention to
possible side effects of a prescribed drug.
Knowledge and evaluation of off-label use of drugs (Table 3)
The parents' wish for information about prescribed drugs
stands in stark contrast to their actual knowledge of the
practise of off-label use. In group B (healthy children), only
14 parents (28%) were aware that children are sometimes
administered drugs which are not tested and licensed for,
one third (17/33%) were convinced that this is not the case
and 20 parents (39%) admitted that they do not know
(Fig. 1). One may not be surprised by such a ratio in group
B; however, in contrast to our initial assumption, we found
a similar low level of parental awareness in group A. In this
group, 15 parents (35%) were aware of the practise of off-
label use in contrast to 11 parents (26%) who thought that
this was not the case and 16 parents (37%) who answered ‘I
do not know’ (no statement=1/2%). The results show that
only a small additional percentage of parents of ill children
compared to the parents of healthy children have acquired
knowledge about the off-label use of drugs. No statistically
significant difference could be demonstrated between
groups A and B concerning the parental knowledge on
the off-label use of drugs.
Would knowledge of an off-label use of drugs influence
parents' consent to treatment or would they consider this
information as not being important? In both groups, all of
the 94 participants accorded some importance to the fact
Table 2 Questions concerning the parental knowledge of drug use
Do you ask for the mode of application or action and possible side
effects when the physician prescribes a drug to your daughter/son?
(No/Yes, namely …)
Do you read the instruction leaflet before you give your child a
prescribed drug? (Never/Sometimes/Always/Remarks: …)
Does your physician draw your attention to possible side effects of a
prescribed drug? (Never/Sometimes/Always/Remarks: …)
Table 1 Participants, contact and number of returns
Study
group
Participants Contact Requested
persons
Number
of returns,
n (%)
Group A Parents of
children
with renal
disease
Contact via
Göttingen/
Hanover
University
Hospitals
80 43 (54)
Group B Parents of
healthy
children
Contact via
soccer club
80 51 (64)
Table 3 Questions concerning the knowledge of off-label use of
drugs
Please judge the following statements concerning drugs for children.
Do you think they are right or wrong?
•Drugs for children are different from drugs for adults regarding
dosage, degree of effectiveness and mode of action in the body.
(Yes/No/Do not know)
•Children sometimes receive drugs which are not tested and licensed
for them. (Yes/No/Do not know)
Eur J Pediatr (2009) 168:1473–1478 1475that a drug is licensed or not. Four parents (9%) of group A
and ten parents (20%) of group B would even refuse a
treatment with off-label drugs. Thirty-one parents (72%) of
group A and 26 parents (51%) of group B would agree
‘when there is no other possibility’. Eight parents (19%) of
group A and 15 parents (29%) of group B specified
conditions of consent like, e.g. ‘a life-threatening condition’
or ‘only in extreme situations’. One parent of a healthy
child remarked that such a decision would be ‘very hard
and depends on the situation’. Although the difference
between both groups is statistically not significant (p=
0.11), risk aversion, measured as percentage of refusal of
off-label use, seems to be higher among the parents of
healthy children (group B) than among the parents of ill
children (group A) (Fig. 2; Table 4).
Acceptance of different types of clinical studies
In the third section of the questionnaire, we presented
different research scenarios and asked for parental consent.
The scenarios of clinical studies were described in a short,
simple and easily comprehensible way. Three types of
clinical studies were represented (Table 5).
To assess whether parents are willing to volunteer their
child—in case of illness—for a clinical study, they had to
evaluate three different study scenarios with varying levels
of risk. The results show significant differences between
groups A and B regarding studies 1 (add-on scenario) and 2
(placebo trial), and a comparable outcome in study 3
(optimization study). Whereas almost half of the parents in
group A (21; 49%) would agree to their child's participation
in study 1 (add-on), this was the case in only 11 (22%) of
parents of group B. Correspondingly, ten parents (23%) of
group A and 20 parents (39%) of group B would refuse
participation; 12 parents (28%) of group A and 20 parents
(39%) of group B answered that they did not know how to
decide (p=0.02). The second study scenario (placebo) was
evaluated comparably in group A (yes=20/47%; no=11/
26%; do not know=12/28%). Parents of group B, however,
were more critical. Only ten parents (20%) of group B
would consent to study participation, while 28 parents
(55%) would refuse. One in four (13/26%) of the parents of
group B did not know how to decide. The difference
between groups A and B was statistically highly significant
(p=0.006). The evaluation of the third study (optimization)
showed less remarkable differences. While 17 parents
(40%) of group A would volunteer their child, 12 parents
(28%) would refuse and 14 parents (33%) did not know
how to decide. The results are comparable to those of group
B (yes=19/37%; no=20/39%; do not know=12/24%; p=
0
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40
Yes (35% / 27%)
No (26% / 33%)
Don't know (37% / 39%)
No Statement (2% / 0%)
Group A
(n=43)
Group B
(n=51)
Fig. 1 ‘Children sometimes receive drugs which are not tested and
licensed for them.’ (Group A parents of ill children, Group B parents
of healthy children)
Table 4 Questions regarding the evaluation of off-label use of drugs
To which of the following statements would you agree?
•I would refuse the treatment of my child with a drug which is not
licensed, even when there is no other possibility.
•I would agree to the treatment of my child with a drug which is not
licensed, when there is no other possibility.
•It is not important for me, whether a prescribed drug is licensed or
not.
•Remarks: …
0
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80
Refusal (9% / 20%)
Agreement (72% / 51%)
Under Spec. Circ. (19% / 29%)
Not Important (0% / 0%)
Group A
(n=43)
Group B
(n=51)
Fig. 2 ‘I refuse/agree/agree under special circumstances to the
treatment of my child with an unlicensed drug when there is no other
possibility./It is not important for me, whether a prescribed drug is
licensed or not.’ (Group A parents of ill children, Group B parents of
healthy children)
1476 Eur J Pediatr (2009) 168:1473–14780.45). Thus, in group A, most parents would consent to the
add-on scenario, while scenario 3 (optimization) met the
least acceptance. Parents of healthy children (group B), in
contrast, considered the optimization scenario the most
acceptable one and were most negative in the case of the
placebo scenario (Fig. 3).
Parents who would volunteer their child for either study
did not significantly differ from their more critical counter-
parts with regard to educational status or gender. However,
although statistically not significant, there are some clues
why some parents are less cautious towards study partici-
pation. For the sake of analysis, we made up three
categories: in the first category (‘supporters’), we subsumed
all parents who consented to study participation in at least
two scenarios (32 parents); in the second category (‘indif-
ferents’), those who answered ‘I do not know’ in at least
two cases (30 parents); in the third category (‘refusers’),
those who rejected study participation in at least two study
scenarios (32 parents). Fifteen parents of the supporters
(47%; n=32) answered that their physician always informs
them about a drug's possible side effects, whereas only
eight (27%; n=30) of the indifferent parents and nine (28%;
n=32) of the refusers reported this fact (p=0.19). Fourteen
(44%; n=32) of the supporters knew that children receive
prescribed drugs which are not tested and licensed for them
compared to only seven (24%; n=30) of the indifferent
parents and eight (25%; n=32) of the refusers (p=0.2).
Moreover, the group of supporters comprised the highest
number of parents (30/94 %; n=32) who felt that the off-
label use of drugs is acceptable ‘when there is no other
possibility’ compared to only 24 (75%; n=32) of the
refusers (Fig. 4).
Conclusions
The results of our study show that knowledge of the off-
label use of drugs in paediatrics is rather limited and
astonishingly low—regarding the importance of this topic—
in both groups of parents of chronically ill and healthy
children. Only 31% of the parents (35% in group A and
28% in group B) knew about the practise of off-label
prescriptions whereas 70% were convinced that this was
not the case or were at least unsure about the fact. Regular
contact to health care providers had no substantial effect on
this ratio. This may in part be due to bad memory;
however, all parents declared to actively seek for informa-
tion on drugs administered to their child, as all of them
stated to read the leaflet instruction and nearly all of them
remembered their physician telling them about side effects.
It is difficult to explain the low percentage of informed
Table 5 Types of clinical studies portrayed in the questionnaire
Types of clinical studies
(1) Randomised, double-armed add-on study (standard therapy vs.
standard therapy plus one additional drug); additional blood and
urine samples for research purposes.
(2) Randomised, double-armed placebo study (newly tested drug
vs. placebo); additional blood and urine samples for research
purposes.
(3) Optimization study; test in a paediatric population of a drug
which is already licensed in adult patients; additional blood and
urine samples for research purposes.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Add-on Group A
Placebo Group A
Optim. Group A
Optim. Group B
Add-on Group B
Placebo Group B
Don't know No Yes
Fig. 3 ‘Your child suffers from chronic disease. Would you volunteer
your child for the following study?’ Answers according to decreasing
acceptance
0 20 40 60 80 100
Physician always
informs about
side-effects
Knowledge of off-
label use
Acceptance of
off-label use if no
other possibility
Supporters
Indifferents
Refusers
Fig. 4 Information on side effects, knowledge of off-label use and
acceptance of off-label use in case of no other treatment possibility in
percent of study supporters, indifferent and refusing parents
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where one would expect the hospital paediatricians to have
drawn parents’ attention to the fact of off-label use.
Information about off-label use is not legally required but
only recommended by lawyers in Germany and it is not
known how often physicians follow this recommendation
[17, 18]. The information was possibly not made available
often enough. Paediatricians themselves may get used to the
fact, as off-label prescription is so common, and may forget
about informing parents explicitly and repeatedly. Some
paediatricians might themselves not be fully informed about
the off-label status of the drugs they prescribe.
Once given the information, parents have a distinctive
view of the off-label use of drugs. A significant percentage
of parents of healthy and chronically ill children (15%)
would refuse the use of these drugs, even when there is ‘no
other possibility’, and a large group of parents (25%) would
agree to the off-label use of drugs only under certain
conditions like a life-threatening disease. Given the
importance of parents' values in medical decision making,
our results illustrate why the practise of downplaying off-
label use in the paediatric population and keeping parents
uninformed about the existence of off-label use in paediat-
rics is ethically problematic. Off-label use is the result of a
risk–benefit analysis and thus depends on value judgments
parents are willing and prepared to be involved in.
Moreover, our study results hint at the fact that the well-
informed parent might be more willing to volunteer their
child for study participation and thus help to reduce the
high incidence of off-label administration of drugs. A large
group of parents (52%; n=49) of either sick or healthy
children in our sample consent to participation in at least
one of the described study scenarios. Among the parents of
chronically ill children in our study, the add-on study
scenario received the highest grade of acceptance (49%; n=
21). The readiness to accept clinical research was associated
with parental knowledge of off-label use and a perceived
general tendency of the paediatric consultant to inform about
the side effect of drugs. If paediatricians want investigators
and pharmaceutical companies to provide them with more
scientific evidence on drug therapy, they may have to inform
parents first. This may well help to find patients for the
studies that have to be conducted in the next years.
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